|
Oder wie ernst muss mal solche Aussagen sehen?
We expect to incur significant expenses and operating losses for the foreseeable future as we continue the development and clinical trials of, seek regulatory approval for, and prepare for commercialization of our product candidates and repay our outstanding loan obligations. If we obtain regulatory approval for oliceridine, we expect to incur significant expenses associated with the launch of this product. We will need to obtain substantial additional funding in connection with our continuing operations. We will seek to fund our operations through the sale of equity, debt financings or other sources, including potential collaborations. However, we may be unable to raise additional funds or enter into such other agreements when needed on favorable terms, or at all. If we fail to raise capital or enter into such other arrangements as, and when, needed, we may have to significantly delay, scale back or discontinue our operations, development programs, and/or any future commercialization efforts.
Klar, keiner will eine Verwässerung.
Aber lieber das ATM gegenüber einem Offering mit Warrants. Das Problem ist nur, solange verkauft wird kommt der Kurs nicht aus dem Quark.( steigt nicht :-) )
Cash, cash equivalents, and marketable securities were $63.5 million as of June 30, 2018. The Company expects this amount, together with interest thereon and proceeds from oliceridine ex-U.S. licensing activities, to be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from today’s date.
Bedienen sie das ATM jetzt noch weiter??????
Shares outstanding as of October 31, 2017: 62,300,981
Common Stock outstanding as of March 2, 2018 was 64,785,659.
Shares outstanding as of April 27, 2018: 67,968,713
Shares outstanding as of July 31, 2018: 76,082,280
In the six months ended June 30, 2018, the Company issued and sold 11,064,238 shares of common stock under the Prior ATM Agreement at a weighted average price per share of $1.81
Net cash provided by financing activities was $13.2 million for the six months ended June 30, 2018, which was primarily due to net proceeds of $19.5 million from the sale of common stock through our at-the-market, or ATM, sales facility with Cowen and Company, LLC, or Cowen, offset by principal repayments on our Term Loans of $6.3 million.
Net cash provided by financing activities was $24.0 million for the six months ended June 30, 2017, which was primarily due to net proceeds of $9.9 million from the March 31, 2017 draw of Term Loan C and net proceeds of $13.7 million from the sale of common stock through our ATM sales facility with Cowen.
Prescription Drug User Fee Act (PDUFA) date for oliceridine: November 2, 2018.
http://investors.trevena.com/node/9546/html#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES
http://investors.trevena.com/node/9541/html
In January, 2018, we announced that FDA has accepted the oliceridine injection new drug application for review with a Prescription Drug User Fee Act review date of November 2, 2018.
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
6 | 916 | Trevena - biopharmaceutical company +69,67 % | Balu4u | Dölauer | 19.07.23 17:35 | |
Nach dem Split | Dölauer | 11.11.22 12:44 | ||||
176 | Trevena FDA 2018 Olinvo | OlliCash | joker75 | 25.04.21 00:44 |